HEALTH RELATED QUALITY OF LIFE IN CHILDHOOD CANCER

描述（申请人的描述）迫切需要 制定与健康有关的生活质量的有效和有用措施 （HRQL）治疗儿童癌症。 不断增加的存活率 儿科肿瘤学，目前接近70%的整体，要求， 调整优先事项，不仅要寻求治愈方法，还要密切关注 注意治疗的HRQL成本。 治疗成本的关键要素 包括与短期和长期毒性相关的发病率， 以及与疾病本身的后遗症相关的发病率。 一 设计儿童癌症新临床试验的关键问题是如何 以降低治疗的发病率而不影响生存率。 这些 发病率现在可以用新出现的措施客观地量化 的HRQL。 在治疗过程中测量患者的HRQL将 提供对患者、家属和卫生保健提供者有帮助的信息 面临着关于替代治疗的艰难决定。 同样地， 关于长期幸存者的HRQL信息将有助于决策 在诊断的时候。 然而，进一步的实质性进展需要 识别、接受和使用经验证的HRQL测量。 的 拟议的国际科学讲习班的主要目的， 儿童癌症患者的健康相关生活质量”， 积累和交流关于在全球范围内测量HRQL的信息， 童年时期的癌症。 六个具体目标中的每一个 研讨会将在一个单独的会议上由3至5名特邀发言者发言 根据提交的摘要选择。 此外，邀请 讨论者将提供该领域的综合总结，并定义 在最后一天向与会者介绍未来的发展方向。 所有 发言稿将以全文稿的形式出版，作为 国际癌症杂志。

DESCRIPTION (Applicant's Description) There is a critical need for the development of valid and useful measures of health-related quality of life (HRQL) for children with cancer. The ever-increasing survival rates in pediatric oncology, presently approaching 70 percent overall, demand that priorities be modified to not only seek cure but to also focus close attention on the HRQL costs of cure. Key elements of the cost of cure include the morbidity associated with short-term and long-term toxicities, and the morbidity associated with the sequelae of the disease itself. A critical issue in designing new clinical trials for childhood cancer is how to reduce the morbidity of treatment without compromising survival. These morbidities can now be quantified objectively with newly emerging measures of HRQL. Measuring HRQL of patients during the process of treatment would provide information helpful to patients, families, and health-care providers faced with difficult decisions about treatment alternatives. Similarly, HRQL information on long-term survivors would help to inform decision-making at the time of diagnosis. However, further substantive progress requires the identification, acceptance, and use of validated HRQL measures. The primary aim of the proposed international scientific workshop, "Assessing Health-Related Quality of Life in Childhood Cancer," is to advance the accumulation and exchange of information on the measurement of HRQL in the context of cancer during childhood. Each of six specific objectives of the workshop will be addressed in a separate session by, 3 to 5 invited speakers chosen on the basis of submitted abstracts. In addition, invited discussants will provide a integrative summary of the field and define potential future directions to the participants on the final day. All presentations will be published in full manuscript format as a supplement to the International Journal of Cancer.